Compare DCX & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DCX | GLMD |
|---|---|---|
| Founded | 2009 | 2000 |
| Country | China | Israel |
| Employees | 1389 | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9M | 4.4M |
| IPO Year | N/A | 2013 |
| Metric | DCX | GLMD |
|---|---|---|
| Price | $1.71 | $0.49 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 22.8K | 19.9K |
| Earning Date | 03-24-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.34 | $0.41 |
| 52 Week High | $5.68 | $2.67 |
| Indicator | DCX | GLMD |
|---|---|---|
| Relative Strength Index (RSI) | 49.05 | 41.43 |
| Support Level | $1.55 | $0.50 |
| Resistance Level | $2.18 | $0.69 |
| Average True Range (ATR) | 0.23 | 0.05 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 43.69 | 46.21 |
Digital Currency X Technology Inc, formerly Chijet Motor Company Inc is engaged in the development, manufacture, sales, and service of new energy vehicles (NEV), hybrid vehicles and traditional fuel vehicles in China. New energy vehicles refer to plug-in electric vehicles, including battery electric vehicles, plug-in hybrid (PHEV) electric vehicles, and fuel cell electric vehicles. Its passenger vehicles include small cars, sedans, and sports utility vehicles, or SUVs, and commercial vehicles include light trucks and vans. The company generates all of its revenue from PRC.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.